Loading clinical trials...

Group Interventions for Breast Cancer Survivors | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Group Interventions for Breast Cancer Survivors

Development of Group Interventions for Breast Cancer Survivors

NCT01775085•Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to compare two types of groups for breast cancer survivors: a Meaning-Centered Group and a Discussion Group. Many breast cancer survivors seek help to deal with the emotional burden of having gone through the cancer experience. Participation in groups offering support often helps cancer survivors cope with stressors of life after having had cancer by giving them a place to express their feelings. The "Meaning-Centered Group" is intended to teach breast cancer survivors how to maintain or even increase a sense of meaning and purpose in their lives after treatment for cancer. The "Discussion Group" is intended to help breast cancer survivors cope by giving them a place to get support from other breast cancer survivors. The goal of this study is to compare the benefits of these two types of group approaches for breast cancer survivors. The study is also testing the benefits and feasibility of conducting the groups virtually using a telephone and computer.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•History of non-metastatic breast cancer (DCIS or Stage I, II, or III) as recorded in the medical record at MSKCC by self-report, or by outside correspondence, including a study checklist signed by a physician for patients outside of MSKCC
•Post completion of treatment (may be on hormone therapy, such as Tamoxifen or monoclonal antibody, such as Herceptin or Pertuzumab)) for any type of cancer as confirmed by the medical record at MSKCC, by self-report, or by outside correspondence, including a study checklist signed by a physician for patients outside of MSKCC
•Age 18 or older
•Access to a telephone, computer (e.g. desktop, laptop, smartphone, tablet) and Internet
•For Phase 2 only:
•A score of ≥ to 4 on the Distress Thermometer (DT) and indication that this distress is related in some way to the patient's breast cancer or survivorship
•If taking medication for mood, anxiety, depression, thoughts, sensory experiences such as hallucinations, or sleep, stable and consistent enough in dosage and use of that medication so as to not result in a clinically significant change as determined by the study PI/co-PI or, confirmed by reports in the medical record at MSKCC, by selfreport, or by outside correspondence, including a study checklist signed by a physician for patients outside of MSKCC
•Did not participate in Phase 1

Exclusion Criteria

•Evidence of or treatment metastatic disease
•Significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the groups (i.e., acute psychiatric symptoms which require individual treatment).

Locations (2)

Memorial Sloan Kettering Cancer Center at Commack

Commack, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Key Dates

Start Date

January 1, 2013

Primary Completion Date

January 1, 2027

Completion Date

January 1, 2027

Last Updated

February 5, 2026

Enrollment

104

ACTUAL participants

Conditions

Breast Cancer Survivor

Interventions

manualized group intervention

BEHAVIORAL

standardized, manualized group intervention

BEHAVIORAL

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

NCT07379918

Breast Cancer (Early Breast Cancer)Breast Cancer Survivors+3 more

View study

RECRUITINGPHASE2

Patient Priorities for Survivorship Care in Older Breast Cancer Survivors

NCT06478589

Breast Cancer Survivorship

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Group Interventions for Breast Cancer Survivors

Inclusion Criteria

Exclusion Criteria

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

Patient Priorities for Survivorship Care in Older Breast Cancer Survivors

Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer Survivors

Motor-cognitive Training Effects on Cognition in Breast Cancer Survivors: the BRAINonFIT Study (BRAINonFIT).

Physical Activity Promotion for Breast and Endometrial Cancer Survivors

Concurrent Exercise in Combination With Music Listening in Female Breast Cancer Survivors